A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 StudyErica Brivio, C. Michel Zwaan, Marta López‐Yurda et al.|Blood|2019Cited by 8
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trialAlexander Schmitz, Karen Dybkær, Anders Waage et al.|BMC Cancer|2022Cited by 7